Form 4: HealthEquity CTO Sells Over 10,000 Shares
Insider Transaction Report
HealthEquity's EVP and Chief Technology Officer, Elimelech Rosner, sold 10,959 shares of common stock for approximately $1.04 million under a pre-arranged trading plan.
Summary
- Elimelech Rosner, the Executive Vice President and Chief Technology Officer of HealthEquity, Inc. (HQY), reported the sale of 10,959 shares of the company's common stock.
- The transaction took place on December 18, 2025.
- The shares were sold at a weighted average price of $95.4549 per share, with individual sale prices ranging from $95.40 to $95.67.
- The total value of the shares sold amounts to approximately $1,046,000.
- Following this transaction, Mr. Rosner beneficially owns 45,742 shares of HealthEquity common stock.
- The sale was executed pursuant to a Rule 10b5-1(c) trading plan, indicating it was a pre-arranged transaction.
Sentiment
Score: 5
Explanation: The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which is generally considered neutral. While it reduces insider ownership, the pre-planned nature mitigates negative sentiment as it is typically for personal financial planning rather than a signal about the company's future.
Negatives
- The transaction represents a reduction in insider ownership, which can sometimes be perceived negatively by investors, although it was pre-planned.
Future Outlook
NA
Industry Context
This filing is specific to an insider transaction at HealthEquity and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders may observe a reduction in insider ownership, but the pre-planned nature of the sale under a Rule 10b5-1 plan suggests it is for personal financial management rather than a reflection of management's immediate outlook on the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 07/07/2023 | Power of Attorney given by Mr. Rosner was previously filed with the U.S. Securities and Exchange Commission. |
| 12/18/2025 | Date of the reported transaction for the sale of common stock. |
| 12/19/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThe filing reports a routine insider sale under a Rule 10b5-1 plan, which is a pre-scheduled event for personal financial management. This type of transaction typically does not indicate a change in the company's fundamentals or future prospects, thus a 'hold' recommendation is appropriate as it provides no new information to alter an existing investment thesis.
Keywords
HealthEquity, HQY, Insider Trading, Form 4, Stock Sale, Elimelech Rosner, Chief Technology Officer, Equity Transaction, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.